INNOVATE Corp: The Steel Behind the AI Buildout, and the Balance Sheet in the Way

Q1 2026: Infrastructure backlog surges on AI-driven construction while capital structure overhang lingers.

HCHC · Earnings Call · 2026-05-14

AI Capex Is Now a Steel Order

INNOVATE Corp’s first-quarter results are a reminder that the AI buildout doesn’t stop at GPU clusters — it gets bolted on with steel. Consolidated revenue rose 33% year-over-year to $364.8 million, powered by DBM Global’s commercial structural steel fabrication, which drove Infrastructure revenue to $357.9 million and adjusted EBITDA to $23 million. Management was explicit about the driver:

We see a lot of capital is moving into physical infrastructure for computing in the United States. We are specifically seeing opportunities in technology-related construction markets and are concentrated around <keyword id="17e97aa6f2">AI infrastructure</keyword>, energy systems, advanced manufacturing and digital connectivity.
Paul Voigt, Interim CEO · 2026-05-14

That language places INNOVATE squarely in the global AI data centers theme that’s been driving advancers across the tape — from hyperscalers to chipmakers. The company’s adjusted backlog held steady at $1.8 billion, and management noted “early success in building backlog for 2027.” — Paul Voigt, Interim CEO · 2026-05-14 The durability of this revenue base is reinforced by the same computing infrastructure spending that other reporters are citing this season; it’s no longer a niche — it’s the order book. Meanwhile, the tariff anxiety that dominated the prior year’s discussion has receded. On the 2025 call, management had downplayed tariff risk, noting: “typically, when DBM goes out and bids their projects, they are locking in prices with the mills.” — Mike Sena, Chief Financial Officer · 2025-03-31 In the current quarter, tariffs aren’t even mentioned — the growth narrative has shifted to AI-driven demand rather than trade policy.

Life Sciences and Spectrum: Milestones, Not Yet Revenue

The life sciences division is a story of regulatory progress rather than top-line growth. MediBeacon secured a CE mark for its renal monitor and earned multiple FDA IDE approvals for clinical studies, including for a wireless sensor and a renal functional reserve study. Management framed the regulatory momentum as enabling a streamlined path across geographies: “MediBeacon now has access to a streamlined approach for existing and eventual approvals in the United States, Europe, Japan, Australia, Canada and Brazil.” — Paul Voigt, Interim CEO · 2026-05-14 That’s meaningful for the regulatory approval process, but the near-term revenue remains tiny — R2 posted only $1.6 million in worldwide revenue, though demand reached $2.2 million and it enters Q2 with a backlog of ~160 systems. R2 is also seeking external capital, an acknowledgment that the commercialization runway still needs funding. Similarly, Spectrum’s revenue declined to $5.3 million, but the company filed for over 60 new FCC licenses and upgraded 25 Class A stations — building optionality for a future spectrum auction. These are commercial readiness bets, not current cash flow.

The Capital Structure Elephant

The most pressing constraint on INNOVATE is its balance sheet. Despite $134.6 million in cash, total debt stood at $699 million, with PIK interest still accruing. The first quarter net loss attributable to common stockholders was $17.2 million. Management’s message was consistent with prior calls: strategic alternatives are still being explored. As they put it: “we continue to work with our lenders on strategic alternatives as we focus on fixing our capital structure.” — Paul Voigt, Interim CEO · 2026-05-14 This is a theme that predates the current quarter — back in March 2025, the CFO confirmed they had engaged bankers for MediBeacon: “we had indicated that we had hired Bankers. We've been working on this process for some time.” — Mike Sena, Chief Financial Officer · 2025-03-31 The difference now is that the operating businesses are showing enough momentum to potentially derisk those monetization efforts — if the capital structure can hold. The tension is clear: DBM’s AI-driven backlog is real, but the parent’s leverage is the overhang. For investors watching the AI infrastructure trade, INNOVATE offers a levered, steel-and-concrete play on that same megatrend — but the stock’s fate will be decided as much in the lender conversations as on the construction site.